

Health Care: Drugs
Ventrus Biosciences Inc. (VTUS: NASDAQ)
$2.21 0.02 | 0.91%
06/19/13 - 04:00 PM ET
146.88K / 128.20K
Vol / Avg. Vol:
2.20 / 2.19
Open / Prev. Close:
2.17 - 2.27
Today's Range:
Portfolios with VTUS
Latest VTUS Headlines from TheStreet
More Financial News for VTUS
Press Releases for VTUS
- VENTRUS BIOSCIENCES ALERT: Levi & Korsinsky Notifies Investors With Losses On Their Investment In Ventrus Biosciences, Inc. Of Class Action Lawsuit And The Deadline Of July 8, 2013 To Seek A Lead Plaintiff Position - Business Wire 06.18.13 | 12:06 pm
- Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Ventrus Biosciences, Inc. To Contact The Firm - PR Newswire 05.18.13 | 09:05 am
- Ventrus Biosciences, Inc. Sued By Investor - PR Newswire 05.17.13 | 08:05 pm
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Ventrus Biosciences, Inc. - VTUS - PR Newswire 05.15.13 | 01:05 pm
- Bronstein, Gewirtz & Grossman, LLC Announces That A Class Action Has Been Filed Against Ventrus Biosciences, Inc. - PR Newswire 05.10.13 | 04:05 pm
- Bernstein Liebhard LLP Announces That A Class Action Has Been Filed Against Ventrus Biosciences, Inc. - PR Newswire 05.10.13 | 03:05 pm
- Holzer Holzer & Fistel, LLC Announces Investigation Into Ventrus Biosciences, Inc. - Business Wire 02.12.13 | 10:02 am
- Rodman & Renshaw Acts As A Co-Manager To Ventrus Biosciences, Inc. Underwritten Registered Offering Of Common Stock - Business Wire 07.14.11 | 06:07 pm
See All Press Releases
Partner Headlines for VTUS